ITMI20050222A1 - Lipidi cationici per la trasfezione di acidi nucleici - Google Patents

Lipidi cationici per la trasfezione di acidi nucleici

Info

Publication number
ITMI20050222A1
ITMI20050222A1 IT000222A ITMI20050222A ITMI20050222A1 IT MI20050222 A1 ITMI20050222 A1 IT MI20050222A1 IT 000222 A IT000222 A IT 000222A IT MI20050222 A ITMI20050222 A IT MI20050222A IT MI20050222 A1 ITMI20050222 A1 IT MI20050222A1
Authority
IT
Italy
Prior art keywords
alkyl
aryl
nucleic acids
transformation
alkenyl
Prior art date
Application number
IT000222A
Other languages
English (en)
Inventor
Luca Bruche
Luca Chiamenti
Marco Folini
Massimo Frigerio
Maria Angela Greco
Walter Panzeri
Fiorenza Viani
Nadia Zaffaroni
Matteo ZANDA
Original Assignee
Milano Politecnico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milano Politecnico filed Critical Milano Politecnico
Priority to IT000222A priority Critical patent/ITMI20050222A1/it
Priority to EP06711426A priority patent/EP1846378B1/en
Priority to AT06711426T priority patent/ATE504576T1/de
Priority to JP2007554745A priority patent/JP2008530083A/ja
Priority to US11/884,354 priority patent/US7999101B2/en
Priority to PCT/IT2006/000072 priority patent/WO2006087752A2/en
Priority to CA002597903A priority patent/CA2597903A1/en
Priority to DE602006021140T priority patent/DE602006021140D1/de
Publication of ITMI20050222A1 publication Critical patent/ITMI20050222A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/28—Only halogen atoms, e.g. cyanuric chloride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/789—Of specified organic or carbon-based composition in array format
    • Y10S977/79—Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
    • Y10S977/791—Molecular array
    • Y10S977/792—Nucleic acid array, e.g. human genome array
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IT000222A 2005-02-15 2005-02-15 Lipidi cationici per la trasfezione di acidi nucleici ITMI20050222A1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT000222A ITMI20050222A1 (it) 2005-02-15 2005-02-15 Lipidi cationici per la trasfezione di acidi nucleici
EP06711426A EP1846378B1 (en) 2005-02-15 2006-02-13 Cationic lipids for the transfection of nucleic acids
AT06711426T ATE504576T1 (de) 2005-02-15 2006-02-13 Kationische lipide zur transfektion von nukleinsäuren
JP2007554745A JP2008530083A (ja) 2005-02-15 2006-02-13 核酸のトランスフェクション用のカチオン性脂質
US11/884,354 US7999101B2 (en) 2005-02-15 2006-02-13 Cationic lipids for the transfection of nucleic acids
PCT/IT2006/000072 WO2006087752A2 (en) 2005-02-15 2006-02-13 Cationic lipids for the transfection of nucleic acids
CA002597903A CA2597903A1 (en) 2005-02-15 2006-02-13 Cationic lipids for the transfection of nucleic acids
DE602006021140T DE602006021140D1 (de) 2005-02-15 2006-02-13 Kationische lipide zur transfektion von nukleinsäuren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000222A ITMI20050222A1 (it) 2005-02-15 2005-02-15 Lipidi cationici per la trasfezione di acidi nucleici

Publications (1)

Publication Number Publication Date
ITMI20050222A1 true ITMI20050222A1 (it) 2006-08-16

Family

ID=36169111

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000222A ITMI20050222A1 (it) 2005-02-15 2005-02-15 Lipidi cationici per la trasfezione di acidi nucleici

Country Status (8)

Country Link
US (1) US7999101B2 (it)
EP (1) EP1846378B1 (it)
JP (1) JP2008530083A (it)
AT (1) ATE504576T1 (it)
CA (1) CA2597903A1 (it)
DE (1) DE602006021140D1 (it)
IT (1) ITMI20050222A1 (it)
WO (1) WO2006087752A2 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014744A1 (en) * 2008-07-29 2010-02-04 The Scripps Research Institute Inhibitors of hepatitis c virus infection
ES2351756B1 (es) 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
CN114874107B (zh) * 2022-07-12 2022-11-29 中山大学附属第七医院(深圳) 一种氨基脂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
DE2038182C3 (de) * 1970-07-31 1980-10-09 Ciba-Geigy Ag, Basel (Schweiz) 2-Substituierte 4,6-Diamino-stri azine
SU657048A1 (ru) 1974-07-12 1979-04-15 Московский Ордена Ленина И Ордена Трудового Красного Знамени Химикотехнологический Институт Имени Д.И.Менделеева Полиазокрасители триазинового р да дл поливинилхлоридных и каучуковых материалов, целлюлозных, протеиновых и полиамидных волокон
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
DE19528882A1 (de) * 1995-08-05 1997-02-06 Fraunhofer Ges Forschung Poly(melamin)dendrimere und Verfahren zu ihrer Herstellung
DE19636337A1 (de) * 1996-08-30 1998-03-05 Inst Angewandte Chemie Berlin Polyazacalix[5]arene, Verfahren zu ihrer Herstellung und ihre Verwendung
BR9909350A (pt) 1998-04-02 2000-12-12 Aventis Pharma Sa Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico
KR100548983B1 (ko) * 2000-11-02 2006-02-02 (주)마크텍 디지털 증명서의 발급 및 인증을 위한 텍스트의 삽입 방법및 장치
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CN102151273B (zh) * 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物

Also Published As

Publication number Publication date
WO2006087752A3 (en) 2006-11-02
EP1846378B1 (en) 2011-04-06
US20080146518A1 (en) 2008-06-19
DE602006021140D1 (de) 2011-05-19
EP1846378A2 (en) 2007-10-24
ATE504576T1 (de) 2011-04-15
JP2008530083A (ja) 2008-08-07
WO2006087752A8 (en) 2006-12-14
CA2597903A1 (en) 2006-08-24
US7999101B2 (en) 2011-08-16
WO2006087752A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
CY1124357T1 (el) Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων
EA200970311A1 (ru) ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
DE602006014502D1 (de) Pyrazolopyrimidine als zellzyklus-kinasehemmer
TNSN07397A1 (en) Acetylene derivatives
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
HRP20090061T3 (en) Purine derivatives acting as a2a receptor agonists
EA201070874A1 (ru) Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
MY153910A (en) BICYCLIC y-AMINO ACID DERIVATIVE
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
GEP201706728B (en) Noxious organism control agent
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
ATE482221T1 (de) Bisamid-zinkbasen
EA200870191A1 (ru) Новые производные циклической мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназ
WO2009150381A3 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
UY29023A1 (es) Procedimiento de preparacinn de derivados n- piperidino - 1, 5 - difenilpirazol - 3 - carboxamida.-
SE0400850D0 (sv) Novel Compounds
TW200612931A (en) Substituted biphenyl derivatives
ITMI20050222A1 (it) Lipidi cationici per la trasfezione di acidi nucleici
GB0602951D0 (en) Organic Compounds
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
ES2688812T3 (es) Conjugados de LLP2A-bisfosfonato para el tratamiento de la osteoporosis